Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00068042 · ClinicalTrials.gov registry record · Phase 4

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

A Phase 4 study of Acromegaly, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target
20
Study locations

NCT00068042: Completed Phase 4 study of Acromegaly, sponsored by Pfizer.

NCT00068042 is a Phase 4 study of Acromegaly that has completed, run by Pfizer. The registered enrollment target is 100 participants, roughly in line with the 93-participant average among 13 other Acromegaly trials with a reported enrollment target. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00068042, a Phase 4 study of Acromegaly, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

Conditions Studied

Acromegaly

Interventions

  • DRUG Pegvisomant
  • DRUG Sandostatin LAR

Study Locations (20)

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Chicago

Michigan

  • Pfizer Investigational Site - Ann Arbor
  • Pfizer Investigational Site - Ann Arbor

New South Wales

  • Pfizer Investigational Site - Darlinghurst
  • Pfizer Investigational Site - Westmead

Victoria

  • Pfizer Investigational Site - Fitzroy
  • Pfizer Investigational Site - Heidelberg

California

  • Pfizer Investigational Site - Los Angeles

Massachusetts

  • Pfizer Investigational Site - Boston

New York

  • Pfizer Investigational Site - New York

North Carolina

  • Pfizer Investigational Site - Chapel Hill

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2003-04
Est. Completion 2006-05
Phase Phase 4
Pfizer

1,845 total trials

What the finished NCT00068042 record still lists

NCT00068042 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 93-participant average among 13 other Acromegaly trials with a reported enrollment target.

The record links to 1 condition, with Acromegaly appearing as the primary indexed condition, and to 2 interventions - of which Pegvisomant is the first listed.

NCT00068042 names 20 study sites across 16 states, led by Illinois, Michigan, New South Wales.

Frequently Asked Questions

What is clinical trial NCT00068042 about?

NCT00068042 is a clinical study titled "A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly". The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.

What is the current status of trial NCT00068042?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2003-04. Estimated completion is 2006-05.

What conditions does trial NCT00068042 study?

This clinical trial studies the following conditions: Acromegaly.

What interventions are being tested in trial NCT00068042?

The interventions under investigation include: Pegvisomant (DRUG), Sandostatin LAR (DRUG).

Who is sponsoring clinical trial NCT00068042?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00068042 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acromegaly

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00068042's enrollment target sits among peer trials

100 4th of 13 higher than 10 of 13 other Acromegaly trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acromegaly trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00068042, the US trial registry maintained by the National Library of Medicine. NCT00068042 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.